RISCS, Inc. announced today it has joined a new coalition of diverse stakeholders to address drug shortages in the United States. The End Drug Shortages Alliance (EDSA) provides a forum for key stakeholders to take strategic aim at one of health care’s more pressing and enduring issues, drug shortages that disrupt patient care.
“We are excited to announce our membership at the End Drug Shortages Alliance and my appointment to the EDSA Board of Directors,” said Stephen Colvill, Executive Director of RISCS. “Our recently announced pharmaceutical supply chain evaluation programs at RISCS, including a pilot with Vizient, demonstrate that common ground can be found in the industry. We look forward to continuing this momentum with EDSA.”
The End Drug Shortages Alliance was launched in late 2021 to bring together industry stakeholders, including providers, group purchasing organizations, manufacturers, distributors, and other industry thought leaders and champions. Efforts will focus on improving access to medications through greater transparency across market participants, leading to improved quality manufacturing of medications and production of additional supply.
“We are grateful to have RISCS join the alliance to end drug shortages,” said Eric Tichy, division chair of pharmacy supply solutions for Mayo Clinic, who serves as the Chair of the Alliance advisory board. “Collaboration among organizations strengthens our ability to improve the quality of life for patients that rely on these medications. Together, we can make a difference.”
